KIBG advises global MedTech and AI companies on entering new markets — regulatory strategy, international capital, and the commercial traction that turns a launch into a business. The United States is our flagship.
Most firms will help you file. Fewer understand how health systems actually buy, where capital is flowing across borders, and how to build presence that compounds. KIBG works across all three — in the US and beyond.
How each market's regulatory framework applies to your specific product, and the pathway that gets you to market without wasted cycles.
Positioning for the right investors in the right markets — the commercial narrative, the process, and the relationships to raise where the capital is.
Go-to-market built for how a given health system buys: the ICP, the buying process, and the path from pilot to signed contract.
The US offers a unified FDA pathway, the deepest pool of growth capital, and a single domestic market at unmatched scale — advantages that only materialize if you understand the terrain. It is where we have the deepest operating experience.
Europe, Canada, the Gulf, and Asia-Pacific each reward a different playbook. For companies expanding beyond a home market — in either direction — KIBG brings the regulatory, capital, and commercial fluency to enter deliberately rather than opportunistically.
A commercial operator and company builder with a technical foundation — bioengineering and AI by training, commercial leadership by trade. Nathan has built and sold healthcare AI globally, published the clinical work behind it, and operated on the commercial side of scale.
Tell us where you are and where you're headed. We'll respond directly.